KALA Bio completes enrollment in CHASE trial, advancing KPI-012 for treating persistent corneal epithelial defects. Topline ...

The approval and commercialization of Oxervate (cenegermin-bkbj, Dompé) in the United States has improved our ability to treat corneal persistent epithelial defects (PEDs) or corneal ...

Did you know that certain medications can cause symptom of 'Corneal epithelium defect'. Find these drugs listed on the page and be warned of similar symptoms as possible side-effects.

Persistent Corneal Epithelial Defects (PCEDs) occur when the corneal epithelium fails to re-epithelialize and close within 10-14 days following an injury, despite standard treatment.

Shares of Krystal Biotech KRYS gained 3.9% yesterday after the company announced that it had dosed the first patient in a ...

PITTSBURGH, July 09, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the first patient has been dosed in its Phase 1/2 clinical trial (“EMERALD-1”), ...

Loss of corneal epithelium ... The epithelial defect gradually healed during the following month. When he was last examined, on January 18, 1966, vision in the left eye was 20/15.

A 68-year-old insulin-dependent diabetic male patient presented with progressive pain, redness, photophobia, tearing, and decreased vision of 1-month duration in his left eye. He had history of ...

Amgen (AMGN) announced on Monday that a late-stage study evaluating its Bemarituzumab in combination with chemotherapy met ...

In a detail-thin announcement, Amgen said that adding bemarituzumab to chemotherapy improved overall survival, though ...

KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and ...